A strategy for the risk assessment of human genotoxic metabolites

Chemical Research in Toxicology

Volumn 22, Issue 2, 2009, Pages 348-356

  Dobo, Krista L ^a   Obach, R Scott ^a   Luffer Atlas, Debra ^b   Bercu, Joel P ^b  

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DRUG METABOLITE; GLUCURONIDE; HYDROQUINONE; HYDROXYL GROUP; PHENOL; SULFATE;

ABSORPTION; ANIMAL MODEL; ARTICLE; BIOASSAY; CARCINOGENICITY; GENOTOXICITY; HUMAN; METABOLISM; MOUSE; NEOPLASM; NONHUMAN; PROBABILITY; QUANTITATIVE ANALYSIS; RAT; RISK ASSESSMENT;

ANIMALS; BODY BURDEN; CARCINOGENS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MUTAGENICITY TESTS; MUTAGENS; RATS; RISK ASSESSMENT;

RODENTIA;

EID: 62249105894     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx8004339     Document Type: Article

References (38)

1. Ku, W. W., Bigger, A., Brambilla, G., Glatt, H., Gocke, E., Guzzie, P. J., Hakura, A., Honma, M., Maitus, H. J., Obach, R. S., and Roberts, S. (2007) Strategy for genotoxicity testing: metabolic considerations. Mutat. Res. 627, 59-77.
2. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196.
3. United States Food and Drug Administration: Center for Drug Evaluation and Research. (2008) Guidance for Industry Safety Testing of Drug Metabolites, http://www.fda.gov/cder/guidance/6897fnl.pdf.
4. Smith, D. A., and Obach, R. S. (2005) Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33, 1409-1417.
5. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
6. Butterworth, B. E., and Bogdanffy, M. S. (1999) A comprehensive approach for integration of toxicity and cancer risk assessments. Regul. Toxicol. Pharmacol. 29, 23-36.
7. Butterworth, B. E., Conolly, R. B., and Morgan, K. T. (1995) A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. Cancer Lett. 93, 129-146.
8. Clewell, H. (2005) Use of mode of action in risk assessment: past, present, and future. Regul. Toxicol. Pharmacol. 42, 3-14.
9. United States Environmental Protection Agency. (2005) Guidelines for carcinogen risk assessment. EPA/630/P-03/001B. http://www.epa.gov/iris/ cancer032505.pdf.
10. Dourson, M. (1996) Uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24, 107.
11. Dourson, M. L., and Stara, J. F. (1983) Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 3, 224-238.
12. United States Environmental Protection Agency. (2002) A review of the reference dose and reference concentration processes. EPA/630/P-02/002F. http://www.epa.gov/iris/RFD_FINAL[1].pdf.
13. Barlow, S., Renwick, A. G., Kleiner, J., Bridges, J. W., Busk, L., Dybing, E., Edler, L., Eisenbrand, G., Fink-Gremmels, J., Knaap, A., Kroes, R., Liera, D., Muller, D. J., Page, S., Rolland, V., Schlatter, J., Tritscher, A., Tueting, W., and Wurtzen, G. (2006) Risk assessment of substances that are both genotoxic and carcinogenic report of an International Conference organized by EFSA and WHO with support of ILSI Europe. Food Chem, Toxicol. 44, 1636-1650.
14. United States Environmental Protection Agency.(1991) Amendments to the Water Quality Standards Regulation; Compliance With CWA Section 303(c)(2)(B); Proposed Rule. Fed. Regist. 56 (223), 58420-58437.
15. Kroes, R., Renwick, A. G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., Schilter, B., Schlatter, J., van, S. F., Vos, J. G., and Wurtzen, G. (2004) Structure-based thresholds of lexicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 42, 65-83.
16. International Conference on Harmonisation. (1997) Q3C Guideline Residual Solvents. 9.1 Supplement.
17. Committee for Medicinal Products for Human Use, European Medicines Agency. (2007) Guideline on the limits of genotoxic impurities. EMEA/CHMP/QWP/251344/2006. http://www.emea.eu.int/pdfs/human/swp/519902en.pdf.
18. McGovern, T., and Jacobson-Kram, D. (2006) Regulation of genotoxic and carcinogenic impurities in drug substances and products. TrAC 25, 790-795.
19. Jacobson-Kram, D., and McGovern, T. (2007) Toxicological overview of impurities in pharmaceutical products. Adv. Drug Delivery Rev. 59, 38-42.
20. Jacobson-Kram, D., and Jacobs, A. (2005) Use of genotoxicity data to support clinical trials or positive genetox findings on a candidate pharmaceutical or impurity. .now what? Int. J. Toxicol. 24, 129-134.
21. International Conference on Harmonisation. (2006) Q3A(R2): Impurities in new drug substances. http://www.ich.org/LOB/media/MEDIA422.pdf.
22. Müller, L., Mauthe, R. J., Riley, C. M., Andino, M. M., Antonis, D. D., Beels, C., DeGeorge, J., De Knaep, A. G., Ellison, D., Fagerland, J. A., Frank, R., Fritschel, B., Galloway, S., Harpur, E., Humfrey, C. D., Jacks, A. S., Jagota, N., Mackinnon, J., Mohan, G., Ness, D. K., O'Donovan, M. R., Smith, M. D., Vudathala, G., and Yotti, L. (2006) A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. ToxicoL Pharmacol. 44, 198-211.
23. Fiori, J. M., and Meyerhoff, R. D. (2002) Extending the threshold of regulation concept: de minimis limits for carcinogens and mutagens. Regul. Toxicol. Pharmacol. 35, 209-216.
24. Munro, I. C., Kennepohl. E., and Kroes, R. (1999) A procedure for the safety evaluation of flavouring substances. Joint FAO/WHO Expert Committee on Food Additives. Food Chem. Toxicol. 37, 207-232.
25. International Conference on Harmonisation. (1997) M3(R1): Maintenance of the ICH Guideline on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. http://www.ich.org/LOB/media/MEDIA3303.pdf
26. Matthews, E. J., and Contrera, J. F. (2007) In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects. Expert. Opin. Drug Metab. Toxicol. 3, 125-134.
27. Matthews, E. J., Kruhlak, N. L., Cimino, M. C., Benz, R. D., and Contrera, J. F. (2006) An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. Regul. Toxicol. Pharmacol. 44, 83-96.
28. Fung, V. A., Barrett, J. C, and Huff, J. (1995) The carcinogenesis bioassay in perspective: application in identifying human cancer hazards. Environ. Health Perspect. 103, 680-683.
29. Barlow, S. M., Kozianowski, G., Wurtzen, G., and Schlatter, J. (2001) Threshold of toxicological concern for chemical substances present in the diet. Report of a workshop, 5-6 October 1999, Paris, France. Food Chem. Toxicol. 39, 893-905.
30. Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de, V. M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., and Peto, R. (1984) A carcinogenic potency database of the standardized results of animal bioassays. Environ. Health Perspect. 58:9-319, 9-319.
31. Gold, L. S., Slone, T. H., Manley, N. B., Garfinkel, G. B., Hudes, E. S., Rohrbach, L., and Ames, B. N. (1991) The Carcinogenic Potency Database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program. Environ. Health Perspect. 96, 11-15.
32. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N. (1984) The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. Environ. Health Perspect. 58, 1-8.
33. Sawyer, C., Peto, R., Bernstein, L., and Pike, M. C. (1984) Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. Biometrics 40, 27-40.
34. Gaylor, D. W., and Gold, L. S. (1995) Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. Regul. Toxicol. Pharmacol. 22, 57-63.
35. Cheeseman, M. A., Machuga, E. J., and Bailey, A. B. (1999) A tiered approach to threshold of regulation. Food Chem. Toxicol. 37, 387-412.
36. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6, 161-225.
37. Parodi, S., Malacarne, D., and Romano, P. (1991) Are genotoxic carcinogens more potent than non-genotoxic carcinogens? Environ. Health Perspect. 95, 199-204.
38. United States Food and Drug Administration: Center for Drug Evaluation and Research. (2005) Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://www.fda.gov/CDER/GUIDANCE/5541fnl.pdf.